Best of the Week
Most Popular
1. The Trump Stock Market Trap May Be Triggered - Barry_M_Ferguson
2.Why are Central Banks Buying Gold and Dumping Dollars? - Richard_Mills
3.US China War - Thucydides Trap and gold - Richard_Mills
4.Gold Price Trend Forcast to End September 2019 - Nadeem_Walayat
5.Money Saving Kids Gardening Growing Giant Sunflowers Summer Fun - Anika_Walayat
6.US Dollar Breakdown Begins, Gold Price to Bolt Higher - Jim_Willie_CB
7.INTEL (INTC) Stock Investing to Profit From AI Machine Learning Boom - Nadeem_Walayat
8.Will Google AI Kill Us? Man vs Machine Intelligence - N_Walayat
9.US Prepares for Currency War with China - Richard_Mills
10.Gold Price Epochal Breakout Will Not Be Negated by a Correction - Clive Maund
Last 7 days
Halifax Stopping Customers Withdrawing Funds Online - UK Brexit Banking Crisis Starting? - 21st July 19
US House Prices Trend Forecast 2019 to 2021 - 20th July 19
MICROSOFT Cortana, Azure AI Platform Machine Intelligence Stock Investing Video - 20th July 19
Africa Rising – Population Explosion, Geopolitical and Economic Consquences - 20th July 19
Gold Mining Stocks Q2’19 Results Analysis - 20th July 19
This Is Your Last Chance to Dump Netflix Stock - 19th July 19
Gold and US Stock Mid Term Election and Decade Cycles - 19th July 19
Precious Metals Big Picture, as Silver Gets on its Horse - 19th July 19
This Technology Everyone Laughed Off Is Quietly Changing the World - 19th July 19
Green Tech Stocks To Watch - 19th July 19
Double Top In Transportation and Metals Breakout Are Key Stock Market Topping Signals - 18th July 19
AI Machine Learning PC Custom Build Specs for £2,500 - Scan Computers 3SX - 18th July 19
The Best “Pick-and-Shovel” Play for the Online Grocery Boom - 18th July 19
Is the Stock Market Rally Floating on Thin Air? - 18th July 19
Biotech Stocks With Near Term Catalysts - 18th July 19
SPX Consolidating, GBP and CAD Could be in Focus - 18th July 19
UK House Building and Population Growth Analysis - 17th July 19
Financial Crisis Stocks Bear Market Is Scary Close - 17th July 19
Want to See What's Next for the US Economy? Try This. - 17th July 19
What to do if You Blow the Trading Account - 17th July 19
Bitcoin Is Far Too Risky for Most Investors - 17th July 19
Core Inflation Rises but Fed Is Going to Cut Rates. Will Gold Gain? - 17th July 19
Boost your Trading Results - FREE eBook - 17th July 19
This Needs To Happen Before Silver Really Takes Off - 17th July 19
NASDAQ Should Reach 8031 Before Topping - 17th July 19
US Housing Market Real Terms BUY / SELL Indicator - 16th July 19
Could Trump Really Win the 2020 US Presidential Election? - 16th July 19
Gold Stocks Forming Bullish Consolidation - 16th July 19
Will Fed Easing Turn Out Like 1995 or 2007? - 16th July 19
Red Rock Entertainment Investments: Around the world in a day with Supreme Jets - 16th July 19
Silver Has Already Gone from Weak to Strong Hands - 15th July 19
Top Equity Mutual Funds That Offer Best Returns - 15th July 19
Gold’s Breakout And The US Dollar - 15th July 19
Financial Markets, Iran, U.S. Global Hegemony - 15th July 19
U.S Bond Yields Point to a 40% Rise in SPX - 15th July 19
Corporate Earnings may Surprise the Stock Market – Watch Out! - 15th July 19
Stock Market Interest Rate Cut Prevails - 15th July 19
Dow Stock Market Trend Forecast Current State July 2019 Video - 15th July 19
Why Summer is the Best Time to be in the Entertainment Industry - 15th July 19
Mid-August Is A Critical Turning Point For US Stocks - 14th July 19
Fed’s Recessionary Indicators and Gold - 14th July 19
The Problem with Keynesian Economics - 14th July 19

Market Oracle FREE Newsletter

Top AI Stocks Investing to Profit from the Machine Intelligence Mega-trend

The Best Biotech Stocks for 2013 are Now Within Your Reach

Companies / BioTech Jul 22, 2013 - 03:11 PM GMT

By: Money_Morning


Garrett Baldwin writes: Biotech stocks are soaring in 2013 as major innovations in healthcare have offered enormous breakthroughs on once-untreatable diseases and conditions.

But for years, it was tricky to invest in some of today's best biotech companies given their volatility and uncertainty in the industry. For the better part of five years, some of today's leading biotech stocks remained essentially flat.

For some time, it was best to stick to large-scale pharmaceutical companies with a strong yield and avoid mass speculation in hit-or-miss penny stocks.

Well, not any more. Shares of the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) - which tracks industry returns - are up a staggering 42% since the beginning of the year, and the health/biotech industry has the highest returns of any sector for the year.

And you haven't seen anything yet...

With one of the most exciting biotech companies now joining the NYSE and another setting its focus on an uplisting, we're seeing major changes in the biotech industry and investment. And there are companies poised to become the best biotech stocks you can find right now.

Biotech Stocks Soar on Life-Changing Innovations

Many of the best performing stocks offer products and services that weren't even technologically possible just two decades ago. But new levels of biotechnological innovation have opened the door to massive amounts of wealth to investors throughout history.

The biotech industry is the hottest place you can put your money right now.

Since the beginning of the year, a number of biotech stocks have absolutely soared, drawing a lot of attention to the sector and its potential.

Cancer therapy firm Amgen Inc. (NASDAQ: AMGN) is up 24% on the year, biopharma producer Gilead Sciences (NASDAQ: GILD) is up 69%, molecular diagnostic company Myriad Genetics (NASDAQ: MYGN) is up 13%, and global biopharmaceutical company Celgene Corp. (NASDAQ: CELG) is up a whopping 72% in 2013.

In the 1990s, some of these shares were penny stocks, doing their best to survive the trials of speculation while investors parked their money in the booming internet industry.

And while dabbling in penny stocks is a still a bold strategy these days, there is another way to speculate on whether a company is about to enter the mainstream. And this one is far more lucrative in the long-run.

Biotechn Goes Mainstream, Provides Huge Profits

Perhaps the best way to determine a company is about becoming the next breakthrough stock is to explore its uplisting strategy from OTC markets to the major exchanges.

Moving to more liquid exchanges like the New York Stock Exchange or NASDAQ affords companies greater access to retail brokers and institutional investors.

Organovo Holdings (NYSE: ONVO) is a favorite of our technology expert Michael Robinson.

The company moved to the NYSE on July 11, and quickly soared by more than 30%, only to see a bit of a retreat on Friday. The stock is now up more than 70% in a month.

The recent upgrade to the will continue to provide Organovo with access to increased liquidity while reducing trading volatility, a major problem for OTC stocks.

ONVO develops three-dimensional (3D) bio printing technology. This technology enables the creation of functional human tissues on demand for research and medical applications.

The company's 3D NovoGen bio printing technology is almost out of a Hollywood sci-fi film. It enables development of various tissue and cell types, and enables doctors to place cells in desired patterns.

This technology will give doctors the ability to create organs, and cosmetic appendages for patients. Now that ONVO has joined the New York Stock Exchange, the company has been cleared for a huge takeoff.

But there's one more company that investors should consider given its goals of uplisting to a major exchange. The company is Cellceutix Corp. (CTIX.OB).

Cellceutix is in the clinical stage of its drug Kevetrin, a medication for the treatment of various forms of cancer and controlling cell mutations.

According to reports, its active compound P53, "has been shown to play critical roles in the homeostatic health of the human body by activating proteins required to repair DNA and plays a major role in the life cycle of cells by inducing cell cycle arrest and apoptosis to maintain cellular and genetic stability."

The company also recently received approval by the FDA for Prurisol, an anti-Psoriasis drug that has boosted the company's reputation and likelihood of being uplisted.

But the clearest sign of CTIX's potential comes in its recent agreement with Aspire Capital to raise $10 million in financing during the clinical trials for Kevetrin at Harvard Cancer Center, and its CEO's dedication to increasing its valuation.

In an interview with Seeking Alpha in March, the company's CEO Jim Boeheim committed to developing Kevetrin and Prurisol in the near-term, but also stated that "moving to a senior exchange is definitely part of our overall plan to maximize exposure and shareholder value."

Doing so would definitely provide greater exposure to investment and would naturally raise awareness of these two potential life-changing drugs.

There are plenty of biotech stocks out there right now poised for huge profits this year, particularly from those preparing IPOs. This is why investors also need a strategy to know how to price these investment opportunities.

After all, when biotech stocks are soaring like they have this year, you'll want to get every penny you can out of your investment.

Source :

Money Morning/The Money Map Report

©2013 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email:

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules